Eupraxia Pharmaceuticals Inc. (EPRX)
(Delayed Data from NSDQ)
$6.65 USD
+0.69 (11.58%)
Updated Sep 22, 2025 03:59 PM ET
Pre-Market: $5.80 -0.85 (-12.78%) 8:42 AM ET
4-Sell of 5 4
D Value F Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
EPRX 6.65 +0.69(11.58%)
Will EPRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for EPRX
EPRX makes New 52 Week Closing High on September 22
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
EPRX: Cantor Fitzgerald and LifeSci Capital Lead Recent Offering
Eupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50
Eupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50